文献速递消化系统肿瘤

辅助FOLFOX联合或不联合西妥昔单抗治疗全RAS和BRAF野生型III期结肠癌患者

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
PubMed 文献 · Ann Oncol · 2017-01-01

本文为PETACC8试验的辅助研究,在全部RAS和BRAF野生型III期结肠癌患者中分析西妥昔单抗联合FOLFOX对比FOLFOX的疗效。结果显示,在RAS野生型或RAS和BRAF野生型患者中,加用西妥昔单抗未显著改善至复发时间、无病生存期或总生存期(HR 0.77-1.03,所有P > 0.05)。

要点

  • 在RAS野生型或RAS和BRAF野生型III期结肠癌患者中,FOLFOX加用西妥昔单抗未显著改善TTR、DFS或OS。
  • 在RAS突变患者或罕见RAS或BRAF突变患者中,加用西妥昔单抗未显示显著有害。
  • 在全RAS和BRAF野生型患者中,DFS的校正HR为0.76(未达显著),作者认为可能值得开展新的随机对照试验。

核心结论

  • 在全部RAS和BRAF野生型III期结肠癌患者中,FOLFOX加用西妥昔单抗对TTR、DFS或OS的改善未达统计学显著(HR 0.77-1.03,所有P > 0.05)。
  • 尽管未达显著,全RAS和BRAF野生型患者中DFS的校正HR为0.76,倾向于加用西妥昔单抗,作者认为可能值得在此背景下开展新的随机对照试验评估EGFR抑制剂。

研究设计与样本

  • 本文为PETACC8试验的辅助研究,对同意转化研究的PETACC8试验患者使用Ampliseq结肠-肺癌面板第2版对KRAS和NRAS第2、3、4外显子及BRAF第11、15外显子进行测序。
  • 在肿瘤携带RAS和BRAF野生型及RAS突变的患者中,研究西妥昔单抗对至复发时间、无病生存期和总生存期的影响,并检测各单个突变的预后价值。

主要发现

  • 在分析的2559例患者中,745例(29%)已知有KRAS第2外显子突变,163例(6.4%)有BRAF V600E突变。
  • 在剩余1651例患者中,1054例经NGS评估,显示另有227例(21%)有KRAS第2、3、4外显子或NRAS第2、3、4外显子突变,46例(4.4%)新诊断BRAF突变。
  • 在RAS野生型或RAS和BRAF野生型肿瘤患者中,FOLFOX加用西妥昔单抗未显著改善TTR、DFS或OS(HR 0.77-1.03,所有P > 0.05)。
  • 在RAS突变患者或罕见RAS或BRAF突变患者中,加用西妥昔单抗未显示显著有害。
  • 在整个试验人群中,NRAS和KRAS密码子61突变是仅有的与KRAS第2外显子或BRAF V600E突变具有相同不良预后价值的罕见突变。

关键数值与推荐

  • 在RAS野生型或RAS和BRAF野生型肿瘤患者中,加用西妥昔单抗对比未加用,TTR、DFS或OS的HR范围为0.77-1.03,所有P > 0.05。
  • 全RAS和BRAF野生型III期结肠癌患者中,DFS的校正HR为0.76,倾向于加用西妥昔单抗,但未达统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: RAS mutations have been shown to confer resistance to anti- epidermal growth factor receptor (EGFR) treatment. We analysed the results of the PETACC8 trial (cetuximab + FOLFOX vs FOLFOX) in full RAS and BRAF wildtype (WT) patients (pts) with resected stage III colon cancer. PATIENTS AND METHODS: Exons 2, 3 and 4 of KRAS and NRAS, and BRAF exons 11 and 15, were sequenced using the Ampliseq colon-lung cancer panel version 2, in PETACC8 trial pts who consented to translational research. The impact of cetuximab on time to recurrence (TTR), disease-free survival (DFS) and overall survival (OS) was investigated in pts with tumours harbouring RAS and BRAF WT, and RAS mutations. The prognostic value of each individual mutation was also tested. RESULTS: Among the 2559 pts analysed, 745 pts (29%) were known to have KRAS exon 2 mutations and 163 pts (6.4%) the BRAF V600E mutation. Of the remaining 1651 pts, 1054 were assessed by NGS, showing that a further 227 pts (21%) had KRAS exon 2, 3, 4 or NRAS exon 2, 3, 4 mutations, and that 46 pts (4.4%) had a newly diagnosed BRAF mutation. Cetuximab added to FOLFOX did not significantly improve TTR, DFS or OS in pts with RAS WT or RAS and BRAF WT tumours (HR 0.77-1.03, all P > 0.05). Cetuximab addition was not either significantly deleterious in RAS mutant pts or in pts with rare RAS or BRAF mutations. In the overall trial population, NRAS and KRAS codon 61 mutations were the only rare mutations with the same pejorative prognostic value as KRAS exon 2 or BRAF V600E mutations. CONCLUSION: Though not significant, the clinically relevant 0.76 adjusted HR observed for DFS in favour of adding cetuximab to FOLFOX, in full RAS and BRAF WT stage III colon cancer pts, may justify a new randomized controlled trial testing EGFR inhibitors in this setting. CLINICAL TRIAL NUMBER: This is an ancillary study of the PETACC8 trial: EUDRACT 2005-003463-23.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Taieb J, Balogoun R, Le Malicot K, et al. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. Ann Oncol. 2017. PMID: 28031175. doi:10.1093/annonc/mdw687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。